ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pegcetacoplan

Also written as “Pegcetacoplan”, “APL-2” and “PEGCETACOPLAN (APL-2)”.

Its studies are mostly in Geographic Atrophy · Hemoglobinuria, Paroxysmal · Glomerulonephritis, Membranoproliferative · Anemia, Hemolytic, Autoimmune · Macular Degeneration, led by 4 companies.

Drug pagePegcetacoplan: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 10, 201830 company-led studies, 7 open or runningNext primary completion: Jun 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogenits history only244 open or runningphase 3since Apr 10, 2018Oct 8, 2014Jun 25, 2027phase 2 · NCT07215390
Swedish Orphan Biovitrumits history only42 open or runningphase 4since Mar 26, 2026Oct 15, 2021Jan 17, 2031phase 3 · NCT07898774
AbbVie11 open or runningphase 2since Aug 12, 2025Aug 12, 2025Oct 2029phase 2 · NCT07160179
Hoffmann-La Rocheits history only10 open or runningphase 1since Apr 29, 2025Apr 29, 2025none ahead

Also a collaborator on its studies: IQVIA Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named pegcetacoplanINNProposed as its International Nonproprietary Name in WHO's List 118
  2. Aug 12, 2025First study: phase 2 study in Geographic AtrophyFirst studyNCT07160179 · 66 planned · United States

Ahead

  1. Oct 2029Primary completion: phase 2 study in Geographic AtrophyNCT07160179

TargetBeta

C3 →read by rule
“A pegylated peptide inhibitor of human complement components C3 and C3b, ”NCIt, by rule
“Complement C3 inhibitor”ChEMBL 37, by rule

Other programs on C3

ProgramCompanyFurthest phaseStudies
SSS55rule3SBiophase 11

Studies

The one study AbbVie leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160179Geographic Atrophy · United States2RecruitingOct 202966

How it is read

Names in the registry

  • “Pegcetacoplan”, 17 entries
  • “APL-2”, 7 entries
  • “PEGCETACOPLAN (APL-2)”, 2 entries
  • “APL-3007, pegcetacoplan (APL-2)”, 2 entries
  • “Syfovre™”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.